Neurology

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Both bluebird bio and Vertex Pharmaceuticals have received unfavorable opinions from the Office of the Inspector General on the matter.

The cofounder and chief scientific officer at Encoded Therapeutics shared preclinical research with the company’s AAV and miRNA platforms.

In honor of World Brain Day, observed annually on July 22 by patient and clinician communities, CGTLive is taking a closer look at this ongoing study.

Paul Y. Song, MD, the chairman and chief executive officer of NKGen, discussed the potential of SNK01, the company’s autologous natural killer cell therapy, in treating PD.

Passage Bio received the feedback on a proposal to amend the upliFT-D protocol in the context of a Type C meeting process with the FDA.

Review top news and interview highlights from the week ending July 19, 2024.

Longeveron will present updated data from the phase 2a CLEAR MIND study at AAIC 2024 at the end of July.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The FDA announced its START Pilot Program in October 2023 with a similar goal.

Patient enrollment is anticipated to begin in the first quarter of 2025.

The senior researcher at Seattle Children’s discussed the development and validation of A2-CAR-CISC EngTreg cells.

Data from the high-dose cohort of a phase 1/2 clinical trial in South Korea will be shared in Fall 2024.

Despite the improvements, Lexeo was unable to discern a benefit on cardiovascular fitness and Peak VO2 from LX2006 with current measurements.

Ignacio Mata, PhD, an associate professor of neurology at the Cleveland Clinic Lerner Institute, pointed out that genetic forms of PD are relatively well-understood compared to other types.

Review top news and interview highlights from the week ending July 12, 2024.

The chairman and chief executive officer of NKGen discussed the new clinical study design for evaluating the NK cell therapy in PD.

The BCT-006-US trial is set to begin dosing this year.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Treated patients had a –0.2 mean change in cUHDRS compared with a –1.0 change in external control data.

The chairman and chief executive officer of NKGen discussed the mechanism behind the company’s NK cell therapy SNK01 and promising early results in patients with PD.

Catch up on any of the key data updates you may have missed last month, with coverage highlights from the CGTLive™ team.

The clinical professor of neurology and pediatrics at Keck School of Medicine of USC also discussed current strategies with gene therapy administration.

Deborah Phippard, PhD, the chief scientific officer of Precision for Medicine, discussed unique difficulties of designing clinical trials for PD gene therapy candidates.

The chairman and chief executive officer of NKGen discussed the potential of SNK01, the company’s autologous natural killer cell therapy, in treating PD.